What drove the recent move in SANN.SW stock?

The 7.91% rise to CHF14.18 on 10 Feb 2026 was driven by pipeline interest and increased trading activity. No single press release was filed at close; watch clinical updates and the 23 Apr 2026 earnings date for confirmation.

What is Meyka AI’s outlook and forecast for SANN.SW stock?

Meyka AI's forecast model projects a 12-month price of CHF17.14 for SANN.SW stock, implying a **20.88%** upside from CHF14.18. Forecasts are model-based and not guarantees.

What are the main risks for SANN.SW stock investors?

Major risks include negative EPS (**-5.38**), cash burn, small market cap, thin liquidity and binary clinical trial outcomes. Price sensitivity to news and financing events is high.

Which catalysts should traders monitor for SANN.SW stock?

Monitor clinical readouts for vamorolone and POL6014, licensing updates for Raxone rights, and the next earnings announcement on 23 Apr 2026. Volume spikes around these events can move the stock sharply.

CH Stocks

CHF14.18 rise for SANN.SW stock on SIX close: volume-led rebound signals momentum

ByDanny Kontos February 11, 2026

SANN.SW stock jumped 7.91% to CHF14.18 at the SIX close on 10 Feb 2026, driven by a volume spike and a strong intraday rally. Trading volume reached 65,899 shares versus a 50-day average of 80,101, marking active interest despite a below-average relative volume. Santhera Pharmaceuticals Holding AG (SANN.SW) remains a small-cap Swiss biotech with a market cap of CHF185.97m and clear clinical catalysts that traders are watching.